Diffuse gliomas represent the most prevalent primary central nervous system malignancies in adults. Although molecular stratification based on isocitrate dehydrogenase (IDH) mutation status has revolutionized neuro-oncology, significant prognostic variability persists within established subcategories. Consequently, researchers continue to explore cellular and cytoskeletal biomarkers to refine risk prediction. A recent real-world cohort study published in the Journal of Neuro-Oncology examined the prognostic impact of cellular communication and cytoskeletal proteins. Specifically, investigators analyzed how actin expression in gliomas, along with connexin-43 (Cx43) and growth-associated protein 43 (GAP-43), correlates with key clinicopathological features, IDH status, and overall survival. The study offers valuable translational insights into how tumor microenvironment dynamics and cell-to-cell structural networking drive aggressive disease progression. Neuro-oncologists, neuropathologists, and neurosurgeons can leverage these findings to refine risk stratification, tailor post-surgical monitoring strategies, and better comprehend therapeutic resistance mechanisms across different glioma subgroups.

Understanding Cytoskeletal Dynamics and Intercellular Communication in Gliomas

Tumor cells in diffuse and high-grade gliomas establish complex intercellular networks through ultra-long membrane protrusions known as tumor microtubuli. These interconnected cellular bridges facilitate intercellular communication, metabolic resource sharing, homeostatic calcium signaling, and resistance against standard alkylating chemotherapy and radiotherapy. Cytoskeletal proteins, particularly actin, provide the structural framework required for cell motility, invasive growth, and micro-tentacle expansion into healthy brain tissue. Simultaneously, gap junction proteins like connexin-43 mediate direct cytosolic transfer of signaling molecules between adjacent malignant cells. In addition, growth-associated protein 43 plays a crucial role in axonal outgrowth and synaptic remodeling during neurodevelopment and neoplastic infiltration. Although laboratory models previously suggested that these structural proteins influence tumor dissemination, real-world clinical evidence in human surgical cohorts remained limited. Therefore, evaluating their quantitative expression levels in resected patient tissue provides crucial knowledge. By correlating immunohistochemical expression profiles with prospectively tracked patient outcomes, clinicians can better appreciate how cytoskeletal architecture influences biological aggressiveness in adult neuro-oncology.

Role of Actin Expression in Gliomas as a Strong Adverse Prognostic Marker

The clinical investigation evaluated surgical tissue specimens from 134 adult patients who underwent resection for newly diagnosed WHO grade 2 through 4 gliomas. The findings demonstrated that elevated actin expression in gliomas strongly correlates with highly aggressive tumor phenotypes and unfavorable clinical outcomes. Specifically, strong actin expression was significantly associated with higher WHO histological grades, IDH-wildtype molecular status, and preoperative contrast enhancement on magnetic resonance imaging. Furthermore, patients displaying prominent actin expression presented with markedly lower baseline functional status compared to those with reduced expression levels. Crucially, this heightened structural activity translated into severe clinical detriments regarding disease control and survival. Patients exhibiting strong actin expression experienced a median progression-free survival of only 7.2 months, compared to 17.4 months in patients with low expression. Similarly, median overall survival dropped dramatically from 81.5 months in low-actin tumors down to 17.1 months in high-actin tumors. Consequently, robust actin expression serves as a potent independent biomarker for aggressive invasion and rapid disease recurrence.

Connexin-43 Expression and Its Unexpected Onco-Protective Correlation

While actin consistently signaled adverse clinical outcomes, the investigation uncovered a nuanced role for connexin-43 expression. Historically, gap junction communication was hypothesized to uniformly promote tumor connectivity and therapy resistance. However, in this cohort, IDH-wildtype gliomas expressed significantly higher baseline levels of connexin-43 compared to IDH-mutant tumors. Remarkably, among patients harboring IDH-wildtype glioblastomas, elevated connexin-43 expression correlated with significantly prolonged overall survival. This finding suggests that connexin-43 may exert a context-dependent regulatory or onco-protective function within a highly malignant IDH-wildtype background. Higher junctional coupling might stabilize metabolic stress or attenuate detached cell migration, thereby counteracting diffuse brain parenchymal invasion. Conversely, IDH-mutant tumors exhibited lower connexin-43 expression, indicating that metabolic alterations driven by 2-hydroxyglutarate alter gap junction expression pathways. Consequently, connexin-43 expression may provide protective structural constraints specifically within aggressive IDH-wildtype tumor microenvironments, offering new avenues for targeted therapeutic exploration.

Clinical Relevance of GAP-43 and Surgical Safety Parameters

In addition to actin and connexin-43, the research team evaluated growth-associated protein 43 across different clinical diagnostic presentations. Interestingly, significantly reduced GAP-43 expression was observed in incidentally diagnosed gliomas compared to cases presenting with symptomatic neurological deficits. Because incidentally identified tumors frequently represent earlier, less invasive stages, reduced GAP-43 levels likely reflect lower initial axonal outgrowth and attenuated tumor microtubule formation. Additionally, the researchers investigated whether the expression levels of these cytoskeletal markers influenced perioperative complication rates following neurosurgical resection. Importantly, none of the three proteins—actin, connexin-43, or GAP-43—demonstrated any significant association with postoperative surgical or neurological complications. This safety finding confirms that higher protein expression reflects intrinsic tumor biology and cellular invasiveness rather than inherently elevated perioperative surgical risk. Therefore, neurosurgeons can safely interpret these biomarker profiles as intrinsic indices of long-term biological behavior rather than immediate surgical risk factors, helping guide decisions regarding adjuvant oncological management.

Translational Implications for Clinical Practice and Future Neuro-Oncology Research

Integrating cytoskeletal biomarker profiling into routine neuropathological evaluation holds substantial promise for precision neuro-oncology. Because actin expression strongly tracks with significantly shorter progression-free and overall survival, routine immunohistochemical assessment of actin can identify high-risk patients requiring intensified adjuvant radiochemotherapy or closer radiological surveillance. Moreover, understanding the functional interplay between actin-driven motility and connexin-mediated syncytial networking opens novel avenues for therapeutic development. Molecular therapies aimed at disrupting actin filament dynamics could potentially impair tumor cell invasion and sensitize refractory glioblastoma cells to standard alkylating chemotherapy. Furthermore, elucidating why connexin-43 offers survival benefits in IDH-wildtype tumors could guide novel therapeutic strategies designed to stabilize functional gap junctional intercellular communication. Ultimately, combining routine molecular testing with structural biomarker assessment will enable multidisciplinary neuro-oncology teams to refine prognostication, personalize post-resection patient care, and develop targeted therapies capable of disrupting the protective cellular networks formed by invading glioma cells.

Frequently Asked Questions

How does actin expression in gliomas impact patient survival?

Elevated actin expression in gliomas strongly correlates with shorter survival. Patients with high actin expression exhibit a median overall survival of 17.1 months compared to 81.5 months in low-expression cases. Similarly, median progression-free survival drops from 17.4 months to 7.2 months, highlighting its role as an adverse prognostic marker.

What is the relationship between connexin-43 and IDH status in gliomas?

IDH-wildtype gliomas show significantly higher connexin-43 expression than IDH-mutant tumors. Notably, within IDH-wildtype gliomas, higher connexin-43 expression correlates with prolonged overall survival, suggesting an unexpected onco-protective or regulatory role for gap junctions in this aggressive molecular subgroup.

Does high expression of cytoskeletal proteins increase perioperative surgical risk?

No, the study demonstrated that expression levels of actin, connexin-43, and GAP-43 do not correlate with perioperative surgical complications. Consequently, these proteins serve strictly as biological indicators of tumor aggressiveness and survival rather than factors affecting immediate surgical outcomes or resection safety.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Krigers A et al. Actin, connexin-43 and GAP-43 expression in gliomas: real-world associations with IDH status, tumor burden and survival. J Neurooncol. 2026 Aug 08. doi: 10.1007/s11060-026-05745-7. PMID: 42570146.